PanGen Biotech Inc. (KOSDAQ:222110)
South Korea
· Delayed Price · Currency is KRW 4,680.00
-100.00 (-2.09%)
Last updated: Mar 31, 2025
PanGen Biotech Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 1,430 | 45.4 | 838.28 | 8,901 | 8,139 | Upgrade
|
| Short-Term Investments | 10,002 | 149.24 | 2 | 15,199 | 10,550 | Upgrade
|
| Cash & Short-Term Investments | 11,432 | 194.64 | 840.28 | 24,100 | 18,689 | Upgrade
|
| Cash Growth | 5773.48% | -76.84% | -96.51% | 28.95% | -23.29% | Upgrade
|
| Accounts Receivable | 2,959 | 2,208 | 689.81 | 1,089 | 535.34 | Upgrade
|
| Other Receivables | 51.8 | 8.54 | 221.29 | 241.03 | 176.87 | Upgrade
|
| Receivables | 3,261 | 2,330 | 974.1 | 1,393 | 775.21 | Upgrade
|
| Inventory | 6,001 | 6,925 | 6,630 | 4,373 | 3,764 | Upgrade
|
| Prepaid Expenses | 53.96 | 58.91 | 71.41 | 21.39 | 15.49 | Upgrade
|
| Other Current Assets | 20.35 | 333.62 | 60.91 | 1,267 | 847.87 | Upgrade
|
| Total Current Assets | 20,768 | 9,843 | 8,576 | 31,154 | 24,092 | Upgrade
|
| Property, Plant & Equipment | 5,805 | 6,240 | 6,608 | 6,748 | 6,029 | Upgrade
|
| Long-Term Investments | 0 | 0 | 0 | -0 | 0 | Upgrade
|
| Other Intangible Assets | 785.13 | 879.93 | 269.63 | 313.41 | 271.58 | Upgrade
|
| Long-Term Deferred Charges | 2,622 | 3,278 | 3,933 | 4,589 | 5,244 | Upgrade
|
| Other Long-Term Assets | 564.14 | 501.5 | 1,287 | 473.47 | 673.02 | Upgrade
|
| Total Assets | 30,545 | 20,741 | 20,674 | 43,277 | 36,309 | Upgrade
|
| Accounts Payable | 423.33 | 298.82 | 255.48 | 381.91 | 296.57 | Upgrade
|
| Short-Term Debt | 816.3 | 2,014 | - | 18,692 | 18,399 | Upgrade
|
| Current Portion of Leases | 1.84 | 1.69 | 1.56 | 1.43 | - | Upgrade
|
| Other Current Liabilities | 1,657 | 3,396 | 872.49 | 811.14 | 1,395 | Upgrade
|
| Total Current Liabilities | 2,899 | 5,711 | 1,130 | 19,886 | 20,091 | Upgrade
|
| Long-Term Leases | 0.39 | 2.24 | 3.93 | 5.49 | - | Upgrade
|
| Other Long-Term Liabilities | 30 | 30 | 206.41 | 116.22 | 77.31 | Upgrade
|
| Total Liabilities | 5,636 | 8,175 | 3,454 | 22,179 | 22,098 | Upgrade
|
| Common Stock | 6,449 | 5,339 | 5,339 | 5,336 | 4,821 | Upgrade
|
| Additional Paid-In Capital | 67,712 | 57,402 | 57,402 | 57,371 | 47,840 | Upgrade
|
| Retained Earnings | -49,953 | -50,876 | -46,210 | -42,062 | -38,680 | Upgrade
|
| Comprehensive Income & Other | 700.82 | 700.82 | 688.64 | 452.86 | 229.89 | Upgrade
|
| Total Common Equity | 24,909 | 12,566 | 17,219 | 21,098 | 14,211 | Upgrade
|
| Shareholders' Equity | 24,909 | 12,566 | 17,219 | 21,098 | 14,211 | Upgrade
|
| Total Liabilities & Equity | 30,545 | 20,741 | 20,674 | 43,277 | 36,309 | Upgrade
|
| Total Debt | 818.54 | 2,018 | 5.49 | 18,699 | 18,399 | Upgrade
|
| Net Cash (Debt) | 10,614 | -1,823 | 834.79 | 5,402 | 290.4 | Upgrade
|
| Net Cash Growth | - | - | -84.55% | 1760.05% | -95.84% | Upgrade
|
| Net Cash Per Share | 922.27 | -170.60 | 78.21 | 528.69 | 30.13 | Upgrade
|
| Filing Date Shares Outstanding | 12.49 | 10.68 | 10.68 | 10.67 | 9.64 | Upgrade
|
| Total Common Shares Outstanding | 12.49 | 10.68 | 10.68 | 10.67 | 9.64 | Upgrade
|
| Working Capital | 17,869 | 4,132 | 7,447 | 11,267 | 4,001 | Upgrade
|
| Book Value Per Share | 1994.04 | 1176.85 | 1612.67 | 1976.95 | 1473.91 | Upgrade
|
| Tangible Book Value | 24,124 | 11,686 | 16,950 | 20,784 | 13,940 | Upgrade
|
| Tangible Book Value Per Share | 1931.19 | 1094.44 | 1587.42 | 1947.58 | 1445.75 | Upgrade
|
| Land | 1,174 | 1,174 | 1,174 | 1,174 | 1,004 | Upgrade
|
| Buildings | 3,909 | 3,909 | 3,909 | 3,909 | 3,456 | Upgrade
|
| Machinery | 11,766 | 11,545 | 11,434 | 10,381 | 9,811 | Upgrade
|
| Construction In Progress | - | 125.36 | - | 332.66 | 1.11 | Upgrade
|
Updated Mar 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.